ADMA Biologics, Inc. (ADMA)
NASDAQ: ADMA · Real-Time Price · USD
22.33
+0.60 (2.76%)
Apr 24, 2025, 4:00 PM EDT - Market closed
ADMA Biologics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for ADMA Biologics stock have an average target of 22.5, with a low estimate of 14 and a high estimate of 26. The average target predicts an increase of 0.76% from the current stock price of 22.33.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 4, 2025.
Analyst Ratings
The average analyst rating for ADMA Biologics stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $25 | Buy | Reiterates | $25 | +11.96% | Mar 4, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $18 → $26 | Strong Buy | Maintains | $18 → $26 | +16.44% | Nov 8, 2024 |
| Raymond James | Raymond James | Strong Buy Maintains $18 → $25 | Strong Buy | Maintains | $18 → $25 | +11.96% | Nov 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | -19.39% | Oct 14, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $20 | Buy | Reiterates | $20 | -10.43% | Sep 20, 2024 |
Financial Forecast
Revenue This Year
505.14M
from 426.45M
Increased by 18.45%
Revenue Next Year
641.31M
from 505.14M
Increased by 26.96%
EPS This Year
0.72
from 0.81
Decreased by -10.59%
EPS Next Year
1.01
from 0.72
Increased by 38.97%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 524.8M | 703.5M | 862.5M | ||
| Avg | 505.1M | 641.3M | 782.3M | ||
| Low | 480.3M | 592.6M | 720.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 23.1% | 39.3% | 34.5% | ||
| Avg | 18.5% | 27.0% | 22.0% | ||
| Low | 12.6% | 17.3% | 12.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 0.77 | 1.12 | 1.40 |
| Avg | 0.72 | 1.01 | 1.24 |
| Low | 0.68 | 0.91 | 1.11 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -5.4% | 55.1% | 38.8% |
| Avg | -10.6% | 39.0% | 23.3% |
| Low | -16.5% | 25.8% | 10.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.